EP4380638A4 - ANTI-HER2 ANTIBODIES AND THEIR USES - Google Patents

ANTI-HER2 ANTIBODIES AND THEIR USES

Info

Publication number
EP4380638A4
EP4380638A4 EP22853864.1A EP22853864A EP4380638A4 EP 4380638 A4 EP4380638 A4 EP 4380638A4 EP 22853864 A EP22853864 A EP 22853864A EP 4380638 A4 EP4380638 A4 EP 4380638A4
Authority
EP
European Patent Office
Prior art keywords
her2 antibodies
her2
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22853864.1A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4380638A2 (en
Inventor
James LULO
Marco Muda
Shaun MURPHY
Adam PELZEK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abpro Corp
Original Assignee
Abpro Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abpro Corp filed Critical Abpro Corp
Publication of EP4380638A2 publication Critical patent/EP4380638A2/en
Publication of EP4380638A4 publication Critical patent/EP4380638A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP22853864.1A 2021-08-04 2022-08-03 ANTI-HER2 ANTIBODIES AND THEIR USES Pending EP4380638A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163229134P 2021-08-04 2021-08-04
PCT/US2022/039302 WO2023014810A2 (en) 2021-08-04 2022-08-03 Anti-her2 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
EP4380638A2 EP4380638A2 (en) 2024-06-12
EP4380638A4 true EP4380638A4 (en) 2025-06-25

Family

ID=85156304

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22853864.1A Pending EP4380638A4 (en) 2021-08-04 2022-08-03 ANTI-HER2 ANTIBODIES AND THEIR USES

Country Status (7)

Country Link
EP (1) EP4380638A4 (https=)
JP (1) JP2024531913A (https=)
KR (1) KR20240040101A (https=)
CN (1) CN117980888A (https=)
AU (1) AU2022324015A1 (https=)
CA (1) CA3228259A1 (https=)
WO (1) WO2023014810A2 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016014942A1 (en) * 2014-07-25 2016-01-28 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
EP3192812A1 (en) * 2013-12-17 2017-07-19 Genentech, Inc. Anti-cd3 antibodies and methods of use
WO2019034580A1 (en) * 2017-08-14 2019-02-21 Morphosys Ag HUMANIZED ANTIBODIES FOR CD3

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3192812A1 (en) * 2013-12-17 2017-07-19 Genentech, Inc. Anti-cd3 antibodies and methods of use
WO2016014942A1 (en) * 2014-07-25 2016-01-28 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
WO2019034580A1 (en) * 2017-08-14 2019-02-21 Morphosys Ag HUMANIZED ANTIBODIES FOR CD3

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOUDOT ET AL: "ABP-100: A tetravalent bispecific T-cell engaging antibody for HER21 solid tumors", ANNALS OF ONCOLOGY, vol. 29, 1 October 2018 (2018-10-01), pages viii417 - viii418, XP093218488, ISSN: 0923-7534, Retrieved from the Internet <URL:https://pdf.sciencedirectassets.com/321639/1-s2.0-S0923753418X68008/1-s2.0-S0923753419496270/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEMj//////////wEaCXVzLWVhc3QtMSJHMEUCICeZotmb7u/o9E/Wk1R+pbgiswiQKG7Wb8zGb3JzfeviAiEAoOwAKtkL8WPDNtNrz9y16zzNkWPrlNJhPQyT5C3S/pgqsgUIQRAFGgwwNTkwMDM1NDY4NjUiDOqZA> DOI: 10.1093/annonc/mdy288 *
DU JUANJUAN ET AL: "Engineering Bifunctional Antibodies with Constant Region Fusion Architectures", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 139, no. 51, 14 December 2017 (2017-12-14), pages 18607 - 18615, XP055958145, ISSN: 0002-7863, DOI: 10.1021/jacs.7b09641 *
T. T. JUNTTILA ET AL: "Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells", CANCER RESEARCH, vol. 74, no. 19, 1 October 2014 (2014-10-01), pages 5561 - 5571, XP055216350, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-13-3622-T *
YU SHENGNAN ET AL: "A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 38, no. 1, 14 August 2019 (2019-08-14), XP055923522, Retrieved from the Internet <URL:https://jeccr.biomedcentral.com/track/pdf/10.1186/s13046-019-1354-1.pdf> DOI: 10.1186/s13046-019-1354-1 *

Also Published As

Publication number Publication date
CN117980888A (zh) 2024-05-03
KR20240040101A (ko) 2024-03-27
WO2023014810A2 (en) 2023-02-09
EP4380638A2 (en) 2024-06-12
WO2023014810A9 (en) 2023-04-06
AU2022324015A1 (en) 2024-02-15
CA3228259A1 (en) 2023-02-09
JP2024531913A (ja) 2024-09-03

Similar Documents

Publication Publication Date Title
EP4010378A4 (en) ANTICCR8 MONOCLONAL ANTIBODIES AND USES THEREOF
EP4294840A4 (en) ANTI-CD30L ANTIBODIES AND USES THEREOF
EP4274851A4 (en) MONOCLONAL ANTI-GPRC5D ANTIBODIES AND USES THEREOF
CA3265264A1 (en) CCR8 ANTIBODIES AND THEIR USES
CA3254156A1 (en) Anti-CD84 antibodies and their uses
CA3266237A1 (en) Anti-SARS-CoV-2 antibodies and their uses
CA3260932A1 (en) CD25-SPECIFIC ANTIBODIES AND THEIR USES
HK40112502A (en) Anti-her2 antibodies and uses thereof
WO2023014810A9 (en) Anti-her2 antibodies and uses thereof
HK40076679A (en) Anti-ccr8 monoclonal antibodies and uses thereof
AU2024359715A1 (en) Anti-ny-eso-1 antibodies and uses thereof
AU2024360965A1 (en) Anti-il-4ra antibodies and uses thereof
AU2024312447A1 (en) Anti-klrg1 antibodies and uses thereof
HK40117557A (en) Anti-tnfr2 antibodies and uses thereof
HK40108348A (en) Anti-interleukin-33 antibodies and uses thereof
HK40112310A (en) Anti-vista antibodies and uses thereof
CA3274041A1 (en) Anti-tmprss6 antibodies and uses thereof
CA3270832A1 (en) Anti-ccr8 antibodies and uses thereof
CA3271516A1 (en) Anti-egfrviii antibodies and uses thereof
CA3269272A1 (en) Anti-fgfr2b antibodies and uses thereof
CA3269174A1 (en) Anti-cd122 antibodies and uses thereof
HK40112046A (en) Anti-acvr2a antibodies and uses thereof
HK40110551A (en) Anti-cd161 antibodies and uses thereof
CA3260394A1 (en) ANTI-MYCT1 ANTIBODIES AND THEIR USES
AU2023901399A0 (en) Anti-SARS-CoV-2 antibodies and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240229

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40112502

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61L0009200000

Ipc: C07K0016320000

A4 Supplementary search report drawn up and despatched

Effective date: 20250527

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20250521BHEP

Ipc: A61K 39/395 20060101ALI20250521BHEP

Ipc: C07K 16/28 20060101ALI20250521BHEP

Ipc: C07K 16/32 20060101AFI20250521BHEP